

Douglas G Mcneel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7885316/publications.pdf>

Version: 2024-02-01

118
papers

4,303
citations

94381

37
h-index

128225

60
g-index

120
all docs

120
docs citations

120
times ranked

4886
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted <i>Listeria monocytogenes</i> -based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 219-228.	2.0	12
2	GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2267-2275.	2.0	4
3	Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon γ -mediated suppression of immune checkpoint receptor expression. <i>Oncolmunology</i> , 2022, 11, 2054758.	2.1	7
4	Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). , 2022, 10, e004198.		19
5	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
6	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. <i>Oncolmunology</i> , 2021, 10, 1912892.	2.1	25
7	Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2021, 207, ji2000656.	0.4	3
8	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
9	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020, 12, 2831.	1.7	12
10	Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. <i>Frontiers in Immunology</i> , 2020, 11, 1867.	2.2	7
11	Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5162-5171.	3.2	29
12	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020, 112, 562-573.	3.0	45
13	Androgen deprivation as a tumour-immunomodulating treatment. <i>Nature Reviews Urology</i> , 2020, 17, 371-372.	1.9	0
14	Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. , 2020, 8, e001510.		9
15	Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1661-1669.	2.0	21
16	Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3507-3517.	0.8	43
17	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. , 2019, 7, 23.		20
18	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with ⁸⁹ Zr- ⁶⁴ Cu-Atezolizumab. <i>Bioconjugate Chemistry</i> , 2019, 30, 1434-1441.	1.8	34

#	ARTICLE	IF	CITATIONS
19	Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and <i>Listeria</i> vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. <i>OncImmunology</i> , 2018, 7, e1456603.	2.1	12
20	Therapeutic Cancer Vaccines: How Much Closer Are We?. <i>BioDrugs</i> , 2018, 32, 1-7.	2.2	15
21	Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. , 2018, 6, 21.		33
22	⁸⁹ Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 110-120.	3.3	100
23	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1525-1535.	3.2	153
24	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. <i>Immunology Letters</i> , 2018, 193, 1-10.	1.1	13
25	TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1364-1374.	1.6	36
26	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 25586-25596.	0.8	66
27	Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (AR-LBD). <i>Prostate</i> , 2017, 77, 812-821.	1.2	7
28	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
29	DNA Vaccines. , 2017, , 183-198.		0
30	Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 630-641.	1.6	50
31	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 1782-1789.	2.3	84
32	Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 1074-1085.	1.6	22
33	Androgen deprivation and immunotherapy for the treatment of prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, T297-T310.	1.6	96
34	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 162-168.	2.8	152
35	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. , 2017, 5, 56.		9
36	DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 168-168.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Preclinical and clinical development of DNA vaccines for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 193-204.	0.8	31
38	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
39	TCR diversity â€“ a universal cancer immunotherapy biomarker?. , 2016, 4, 69.		18
40	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. <i>Oncoimmunology</i> , 2016, 5, e1165377.	2.1	42
41	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1487-1492.	2.8	77
42	Immunotherapy for prostate cancer: False promises or true hope?. <i>Cancer</i> , 2016, 122, 3598-3607.	2.0	22
43	Mini-intronic plasmid vaccination elicits tolerant LAG3 ⁺ CD8 ⁺ T cells and inferior antitumor responses. <i>Oncoimmunology</i> , 2016, 5, e1223002.	2.1	10
44	B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. <i>Oncotarget</i> , 2016, 7, 67901-67918.	0.8	21
45	Inducible expression of cancer-testis antigens in human prostate cancer. <i>Oncotarget</i> , 2016, 7, 84359-84374.	0.8	17
46	SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50997-51011.	0.8	9
47	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitopeâ€“Modified DNA Vaccine Immunization. <i>Cancer Immunology Research</i> , 2015, 3, 946-955.	1.6	66
48	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2469-2474.	1.4	26
49	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4500-4500.	0.8	11
50	A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. <i>Cancer Immunology Research</i> , 2014, 2, 988-999.	1.6	45
51	DNA Vaccines. , 2014, , 1-16.		0
52	Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3692-3704.	3.2	41
53	DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8 ⁺ T-cell immune responses. <i>Vaccine</i> , 2014, 32, 1707-1715.	1.7	16
54	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5012-5012.	0.8	30

#	ARTICLE	IF	CITATIONS
55	Engineering DNA Vaccines for Cancer Therapy. , 2014, , 449-471.		0
56	Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. , 2013, 1, 2.		2
57	The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunology, Immunotherapy, 2013, 62, 585-596.	2.0	26
58	A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy. Clinical Genitourinary Cancer, 2013, 11, 407-415.	0.9	11
59	Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2013, 31, 135-135.	0.8	1
60	Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chinese Clinical Oncology, 2013, 2, .	0.4	3
61	Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncolmmunology, 2012, 1, 1546-1556.	2.1	10
62	Vaccination using peptides spanning the SYTâ€“SSX tumor-specific translocation. Expert Review of Vaccines, 2012, 11, 1401-1404.	2.0	7
63	DNA Vaccines for Prostate Cancer. Current Cancer Therapy Reviews, 2012, 8, 245-253.	0.2	8
64	Human Prostate Tumor Antigenâ€“Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade. Journal of Immunology, 2012, 189, 5590-5601.	0.4	96
65	Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Review of Vaccines, 2012, 11, 1315-1317.	2.0	35
66	Lenalidomide modulates ILâ€“8 and antiâ€“prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate, 2012, 72, 487-498.	1.2	13
67	Identification of prostatic acid phosphatase (PAP) specific HLAâ€“DR1â€“restricted tâ€“cell epitopes. Prostate, 2012, 72, 730-740.	1.2	6
68	T cells localized to the androgenâ€“deprived prostate are T_H1 and T_H17 biased. Prostate, 2012, 72, 1239-1247.	1.2	19
69	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunology, Immunotherapy, 2012, 61, 1137-1147.	2.0	85
70	DNA Vaccines for Prostate Cancer. Current Cancer Therapy Reviews, 2012, 8, 245-253.	0.2	0
71	Vaccines Targeting the Cancer-testis Antigen SSX-2 Elicit HLA-A2 Epitope-specific Cytolytic T Cells. Journal of Immunotherapy, 2011, 34, 569-580.	1.2	31
72	CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunology, Immunotherapy, 2011, 60, 781-792.	2.0	23

#	ARTICLE	IF	CITATIONS
73	Pilot trial of interleukin-2 and zoledronic acid to augment $\hat{I}^3\hat{I}$ T cells as treatment for patients with refractory renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1447-1460.	2.0	127
74	Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. <i>Prostate</i> , 2011, 71, 134-146.	1.2	11
75	Sipuleucel-T: immunotherapy for advanced prostate cancer. <i>Open Access Journal of Urology</i> , 2011, 3, 49.	0.3	4
76	Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 6785-6795.	0.4	53
77	IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	14
78	DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer. <i>Journal of Immunotherapy</i> , 2010, 33, 639-647.	1.2	104
79	HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 943-953.	2.0	47
80	Identification of Autoantibodies in a Patient With Testicular Cancer and Concurrent Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, e680-e683.	0.8	1
81	Reply to M.R. Smith et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e59-e59.	0.8	0
82	The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-18.	3.3	80
83	Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. <i>Human Immunology</i> , 2010, 71, 496-504.	1.2	81
84	DNA vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2010, 9, 731-745.	2.0	28
85	Prioritization of cancer antigens: keeping the target in sight. <i>Expert Review of Vaccines</i> , 2009, 8, 1657-1661.	2.0	13
86	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. <i>Clinical Cancer Research</i> , 2009, 15, 3406-3415.	3.2	38
87	Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF. <i>Cancer Research</i> , 2009, 69, 609-615.	0.4	238
88	Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage DO Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4047-4054.	0.8	214
89	An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. <i>Journal of Clinical Investigation</i> , 2009, 119, 2031-41.	3.9	44
90	His-tag ELISA for the detection of humoral tumor-specific immunity. <i>BMC Immunology</i> , 2008, 9, 23.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Endothelin Receptor Antagonists in Cancer Therapy. <i>Cancer Investigation</i> , 2007, 25, 785-794.	0.6	56
92	Prostate cancer immunotherapy. <i>Current Opinion in Urology</i> , 2007, 17, 175-181.	0.9	23
93	MAD-CT-2 Identified as a Novel Melanoma Cancer-testis Antigen Using Phage Immunoblot Analysis. <i>Journal of Immunotherapy</i> , 2007, 30, 675-683.	1.2	13
94	GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1893-1902.	1.4	49
95	Cellular immunotherapies for prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 315-322.	2.5	11
96	Antibody and Tâ€cell responses specific for the androgen receptor in patients with prostate cancer. <i>Prostate</i> , 2007, 67, 1729-1739.	1.2	25
97	Inducible expression of a prostate cancerâ€™testis antigen, SSXâ€2, following treatment with a DNA methylation inhibitor. <i>Prostate</i> , 2007, 67, 1781-1790.	1.2	48
98	Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 885-895.	2.0	51
99	Immunotherapy for prostate cancer - recent progress in clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 465-74, 477-9.	0.3	8
100	New approaches to identification of antigenic candidates for future prostate cancer immunotherapy. <i>Update on Cancer Therapeutics</i> , 2006, 1, 273-284.	0.9	4
101	Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). <i>Vaccine</i> , 2006, 24, 293-303.	1.7	52
102	Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. <i>International Journal of Urology</i> , 2006, 13, 211-217.	0.5	26
103	Effects of a monoclonal anti-Î±vÎ²3 integrin antibody on blood vesselsâ€™A pharmacodynamic study. <i>Investigational New Drugs</i> , 2006, 25, 49-55.	1.2	32
104	Humoral immune responses to testis antigens in sera from patients with prostate cancer. <i>Cancer Immunity</i> , 2006, 6, 1.	3.2	32
105	Antigen-Specific IgG Elicited in Subjects with Prostate Cancer Treated with Flt3 Ligand. <i>Journal of Immunotherapy</i> , 2005, 28, 268-275.	1.2	17
106	Immune-based therapies for prostate cancer. <i>Immunology Letters</i> , 2005, 96, 3-9.	1.1	22
107	Phase I Trial of a Monoclonal Antibody Specific for Î±vÎ²3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion. <i>Clinical Cancer Research</i> , 2005, 11, 7851-7860.	3.2	147
108	A Phase I Study of a DNA Vaccine Targeting Prostatic Acid Phosphatase in Patients with Stage D0 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2005, 4, 215-218.	0.9	11

#	ARTICLE	IF	CITATIONS
109	Prostate cancer antigens and vaccines, preclinical developments. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 247-261.	0.5	11
110	Identification of Antigen-Specific IgG in Sera from Patients with Chronic Prostatitis. <i>Journal of Clinical Immunology</i> , 2004, 24, 492-502.	2.0	47
111	Newer Therapies in Advanced Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2004, 3, 150-156.	2.1	26
112	Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. <i>Journal of Clinical Immunology</i> , 2003, 23, 62-72.	2.0	45
113	Soluble Cytokines Can Act as Effective Adjuvants in Plasmid DNA Vaccines Targeting Self Tumor Antigens. <i>Immunobiology</i> , 2003, 207, 179-186.	0.8	24
114	Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancer. <i>Prostate</i> , 2001, 47, 222-229.	1.2	51
115	Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 62, 245-252.	1.1	139
116	ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 164, 1825-1829.	0.2	69
117	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1999, 93, 2653-2659.	0.6	38
118	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1999, 93, 2653-2659.	0.6	5